We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
In the latest close session, Adma Biologics (ADMA - Free Report) was up +1.87% at $10.33. This change outpaced the S&P 500's 0.47% loss on the day. Meanwhile, the Dow experienced a rise of 0.1%, and the technology-dominated Nasdaq saw a decrease of 1.25%.
Heading into today, shares of the infectious disease drug developer had gained 7.3% over the past month, outpacing the Medical sector's loss of 3.97% and the S&P 500's gain of 1.15%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.19, marking a 18.75% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $139.8 million, indicating a 4.16% growth compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.78 per share and a revenue of $536.82 million, indicating changes of +30% and +5.22%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 13.06. This indicates a discount in contrast to its industry's Forward P/E of 23.26.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 182, which puts it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
In the latest close session, Adma Biologics (ADMA - Free Report) was up +1.87% at $10.33. This change outpaced the S&P 500's 0.47% loss on the day. Meanwhile, the Dow experienced a rise of 0.1%, and the technology-dominated Nasdaq saw a decrease of 1.25%.
Heading into today, shares of the infectious disease drug developer had gained 7.3% over the past month, outpacing the Medical sector's loss of 3.97% and the S&P 500's gain of 1.15%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.19, marking a 18.75% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $139.8 million, indicating a 4.16% growth compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.78 per share and a revenue of $536.82 million, indicating changes of +30% and +5.22%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics is currently sporting a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 13.06. This indicates a discount in contrast to its industry's Forward P/E of 23.26.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 182, which puts it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.